Precision Epigenomics Overview
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$265K
- Investors
-
6
Precision Epigenomics General Information
Description
Operator of a molecular diagnostic company intended to develop molecular diagnostic assays for cancer diagnosis. The company working to develop DNA methylation is an epigenetic change that can be associated with any molecular diagnostic tests for cancer, enabling it to improve cancer diagnosis and treatment, and could lead to the development of new cancer therapies.
Contact Information
Website
www.precision-epigenomics.comCorporate Office
- 630 North Alvernon Way
- Suite 280B
- Tucson, AZ 85711
- United States
Corporate Office
- 630 North Alvernon Way
- Suite 280B
- Tucson, AZ 85711
- United States
Precision Epigenomics Timeline
Precision Epigenomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Debt - General | 22-Sep-2025 | $265K | Completed | Generating Revenue | ||
| 5. Early Stage VC (Series A1) | 11-Sep-2024 | Completed | Generating Revenue | |||
| 4. Grant | Completed | Generating Revenue | ||||
| 3. Accelerator/Incubator | 02-Apr-2024 | Completed | Generating Revenue | |||
| 2. Grant | 01-Feb-2022 | $397K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup |
Precision Epigenomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 |
Precision Epigenomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Precision Epigenomics Patents
Precision Epigenomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026097007-A2 | Compositions and methods for detecting and diagnosing of melanoma | Pending | 01-Nov-2024 | ||
| WO-2026097007-A3 | Compositions and methods for detecting and diagnosing of melanoma | Pending | 01-Nov-2024 |
Precision Epigenomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Precision Epigenomics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DVRGNT Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Shaffer Capital | Corporation | Minority | ||
| Flinn Foundation | Limited Partner | |||
| National Cancer Institute | Government |
Precision Epigenomics FAQs
-
Where is Precision Epigenomics headquartered?
Precision Epigenomics is headquartered in Tucson, AZ.
-
What is the size of Precision Epigenomics?
Precision Epigenomics has 10 total employees.
-
What industry is Precision Epigenomics in?
Precision Epigenomics’s primary industry is Diagnostic Equipment.
-
Is Precision Epigenomics a private or public company?
Precision Epigenomics is a Private company.
-
What is Precision Epigenomics’s current revenue?
The current revenue for Precision Epigenomics is .
-
How much funding has Precision Epigenomics raised over time?
Precision Epigenomics has raised $1.79M.
-
Who are Precision Epigenomics’s investors?
DVRGNT Ventures, , Shaffer Capital, Flinn Foundation, and National Cancer Institute are 5 of 6 investors who have invested in Precision Epigenomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
